Document Detail


Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice.
MedLine Citation:
PMID:  23396731     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
This study aimed to evaluate the efficacy and safety of entecavir and/or tenofovir in compensated (CC) or decompensated (DC) hepatitis B cirrhotic patients in real-life clinical practice. Of the 48 patients, included between April 2007 and March 2010, 12 were DC. The mean age was 55 ± 12.2 years, 85.4% were Caucasians and 8 patients were HBeAg positive. Mean viral load was 5.2 ± 1.9 log10 UI/mL. HBV-DNA undetectability at 3, 6, 12 and 24 months were 53.3%, 78.3%, 83.7% and 97.1%, respectively, similar in CC and DC. At 6 and 12 months, ≥ 80% of CC achieved ALT normalization, while only 42.9% and 71.4% in DC. After a median follow-up of 27.1 (0.7-45.3) months, 43 patients were Child Pugh Turcotte (CPT) class A (n = 39 at entry). In DC, progressive improvement in the MELD scores was observed: 12.73 (SD 4.5), 10.4 (SD 3.6) and 8.2 (SD 2.6), at baseline, 12 and 24 months, respectively. During follow-up, 7 patients died, 4 received liver transplantation and 5 developed hepatocellular carcinoma. In three out of four DC who died due to hepatic causes, these events occurred between the first 0.7 and 6.7 months, and all were CPT class C. Cumulative survival in CC vs. DC at 12 and 24 months were 94.4% vs. 66.7%, and 88.2% vs. 57.1%, respectively (log rank p = 0.03). No severe adverse events associated with entecavir or tenofovir were reported. In conclusion, in compensated and decompensated cirrhotic patients, entecavir and tenofovir were effective and well tolerated.
Authors:
Mireia Miquel; Oscar Núñez; María Trapero-Marugán; Antonio Díaz-Sánchez; Miguel Jiménez; Juan Arenas; Antonio Palau Canós
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Annals of hepatology     Volume:  12     ISSN:  1665-2681     ISO Abbreviation:  Ann Hepatol     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101155885     Medline TA:  Ann Hepatol     Country:  Mexico    
Other Details:
Languages:  eng     Pagination:  205-12     Citation Subset:  IM    
Affiliation:
Department of Gastroenterology, Corporació Sanitària Parc Taulí, Universidad Autónoma de Barcelona, Sabadell. Spain; CIBEREHD, Instituto Carlos III.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Vitamin D deficiency and vitamin D therapy in chronic hepatitis C.
Next Document:  Prevalence and risk factors of isolated anti-HBc antibody and occult hepatitis B infection in hemodi...